Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer

Journal of Pathology

Volumn 179, Issue 1, 1996, Pages 31-38

  Nakopoulou, Lydia L ^a   Alexiadou, Anastasia ^a   Theodoropoulos, George E ^a   Lazaris, Andreas C H ^a   Tzonou, Anastasia ^a   Keramopoulos, Andonis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; c erbB 2; Immunohistochemistry; p53; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029927099     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O     Document Type: Article

References (30)

1. Miller WR, Ellis IO, Sainsbury JRC, Dixon JM. Prognostic factors - ABC of breast diseases Br Med J 1994; 309: 1573-1576
2. Harris CC, Hallstein M Clinical implication of the p53 tumour suppressor gene. N Engl J Med 1993; 329: 1318-1327.
3. Chang F, Syrjanen S, Kurunen K, Syrjanen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993, 88: 174-186
4. Frebourg T, Friend SH The importance of p535 gene alterations in human cancer, is there more than circumstantial evidence? J Natl Cancer Inst 1993; 85: 1554-1557.
5. Zambetti GP, Levine AJ A comparison of the biologic activities of wild type and mutant p53 FASEB J 1993, 7: 855-860.
6. Kaklamams L p53 expression in colorectal adenomas. Am J Pathol 1993; 142: 87-92
7. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS P-glycoprotein, HER-2/neu and mutant p53 expression in human gynecologic tumors J Natl Cancer Inst 1994, 86: 850-855.
8. Tsuda H, Hirohashi S, Shimosato Y. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene coamplification units hst-1/int-2 and c-erbB-2/ear-I. Cancer Res 1989; 49: 3104-3108.
9. Altman DG. Practical Statistics for Medical Research London Chapman & Hall, 1991.
10. Gusterson BA, Gullick WJ, Venter DJ, et al. Immunohistochemical localization of c-erbB-2 in human breast carcinomas Mol Cell Probes 1988; 1: 383-391.
11. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 1993; 12: 2369-2375.
12. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.
13. Thor AD, Moore DH II, Edgerton SM, et al Accumulation of p53 tumor suppressor gene protein an independent marker of prognosis in breast cancers N Natl Cancer Inst 1992, 84: 845-855.
14. Barbareshi M, Leonardi E, Mauri F, Serio G, Palma PD p53 and c-crbB-2 protein expression in breast carcinomas An immunohistochemical study including correlations with receptor status, proliferation markers and clinical stage in human breast cancer Am J Clin Pathol 1992; 98: 408-418.
15. Basnes DM, Dublin EA, Fisher CJ, Levijon DA, Klillis RR Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993; 24: 469-470.
16. Bartek J, Bartkova J, Vojtesek B, et al Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro Int J Cancer 1990, 46: 839-844.
17. Ostrowsky JL, Sawan A, Henry L p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study J Pathol 1991, 164: 75-81.
18. Humphrey PA, Franquemont DW, Geary WA, Kerns BJM, Iglehart JD, Marks JR Immunodetection of p53 protein in noninvasive epithelial proliferative breast disease. Appl Immunohistochem 1994, 2: 22-28
19. Davidoff AM, Kerns BJM, Iglehart JD, Marks J Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991, 51: 2605-2610
20. Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB NM23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993; 85: 727-731
21. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 35S: 846-847.
22. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
23. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF p53 gene mutations and steroid receptor status in breast cancer: clinicopathologic correlations and prognostic assessment Cancer 1994; 73: 2147-2156.
24. Iwaya K, Tsuda H, Hraide H, et al Nuclear p53 immunoreaction associated with prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-840.
25. Borg A, Daldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene 1991; 6: 137-143.
26. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project prognostic significance of c-erbB-2 protein overexpression J Clin Oncol 1990; 8: 103-112.
27. Fuqya SA, Fitzgerald SD, Allred DC. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992, 52: 483-486.
28. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma, preliminary studies support cautious optimism. Editorial. J Natl Cancer Inst 1993, 85.
29. Chang K, Ding I, Kern FG, Willingham MC. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors J Histochem Cytochem 1991; 39: 1281-1287.
30. Dati C, Muraca R, Tazartes O c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome Int J Cancer 1991; 47: 833-838.